Cellectar Announces Poster Presentation of Clinical Data at the American Association of Cancer Research (AACR) Annual Meeting

Jul 21, 2020

Cellectar Appoints Dr. John Friend as Chief Medical Officer

Jul 1, 2020

Cellectar to be Granted EU Patent for Phospholipid Ether (PLE) Analogs as Cancer-Targeting Drug Vehicles

Jun 11, 2020

Cellectar Biosciences Announces Closing of $20 Million Underwritten Public Offering

Jun 5, 2020

Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering

Jun 3, 2020

Cellectar Granted SME Status by the European Medicines Agency

Jun 1, 2020

Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia

May 26, 2020

Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131

May 14, 2020

Cellectar Reports First Quarter 2020 Financial Results and Provides a Corporate Update

May 7, 2020

Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update

Mar 9, 2020